Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Georgios Laliotis"'
Autor:
Shouvonik Sengupta, Kelsi O West, Shridhar Sanghvi, Mireia Guerau-de-Arellano, Georgios Laliotis, Kristin L. Patrick, Harpreet Singh, Kristen W. Lynch, Laura M. Agosto, Philip N. Tsichlis
Publikováno v:
ImmunoHorizons. 5:884-897
Protein arginine methyltransferase (PRMT) 5 is the type 2 methyltransferase catalyzing symmetric dimethylation of arginine. PRMT5 inhibition or deletion in CD4 Th cells reduces TCR engagement-induced IL-2 production and Th cell expansion and confers
Autor:
Xiaojun Ma, Russell Schwartz, Drake Palmer, Georgios Laliotis, Adler Guerrero Zuniga, Eneda Toska, Xinghua Lu, Hatice U. Osmanbeyoglu, Yifeng Tao
Cancer is a disease of gene dysregulation, where cells acquire somatic and epigenetic alterations that drive aberrant cellular signaling. These alterations adversely impact transcriptional programs and cause profound changes in gene expression. Ultim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::11960900fa6cb848c0372c20fc8c66dc
https://doi.org/10.1101/2021.09.07.459263
https://doi.org/10.1101/2021.09.07.459263
Autor:
Harpreet Singh, Kristin L. Patrick, Shouvonik Sengupta, Philip N. Tsichlis, Kelsi O West, Shridhar Sanghvi, Mireia Guerau-de-Arellano, Georgios Laliotis, Laura M. Agosto, Kristen W. Lynch
Protein Arginine Methyltransferase (PRMT) 5 is the major type 2 methyltransferase catalyzing symmetric dimethylation (SDM) of arginine. PRMT5 inhibition or deletion in CD4 Th cells reduces TcR engagement-induced IL-2 production and Th cell expansion
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c1a3dc63c608442665ce2092ec7eca41
https://doi.org/10.1101/2021.08.24.457384
https://doi.org/10.1101/2021.08.24.457384
Autor:
Shouvonik, Sengupta, Kelsi O, West, Shridhar, Sanghvi, Georgios, Laliotis, Laura M, Agosto, Kristen W, Lynch, Philip N, Tsichlis, Harpreet, Singh, Kristin L, Patrick, Mireia, Guerau-de-Arellano
Publikováno v:
Immunohorizons
Protein Arginine Methyltransferase (PRMT) 5 is the major type 2 methyltransferase catalyzing symmetric dimethylation (SDM) of arginine. PRMT5 inhibition or deletion in CD4 Th cells reduces T cell receptor (TCR) engagement-induced interleukin (IL)-2 p
Autor:
Shouvonik Sengupta, Lindsay M Webb, Georgios Laliotis, Philip N Tsichlis, Mireia Guerau-de-Arellano
Publikováno v:
The Journal of Immunology. 204:76.7-76.7
Protein Arginine Methyltransferase (PRMT) 5 is an enzyme catalyzing symmetric dimethylation (SDM) of arginine. This post-translational modification is known to be involved in oncogenesis and embryonic development. Our previous work has shown that PRM
Autor:
Zayda L. Piedra-Quintero, Shouvonik Sengupta, Lindsay M Webb, Stephanie A Amici, Georgios Laliotis, Philip N Tsichlis, Mireia Guerau-de-Arellano
Publikováno v:
The Journal of Immunology. 204:230.1-230.1
PRMT5 catalyzes symmetric dimethylation (SDM) on arginine residues. PRMT5 methylates histone H3 and H4 producing remodeling of chromatin and regulation of gene transcription. PRMT5 is induced after T cell activation. Furthermore, both PRMT5 inhibitor